Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin De Genst

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Protein Engineering, Design & Selection : PEDS|April 13, 2010
A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosisChristine L Hagan, Russell J K Johnson, Anne Dhulesia, et al.
Biophysical Journal|December 8, 2016
The Significance of the Location of Mutations for the Native-State Dynamics of Human LysozymeMinkoo Ahn, Christine L Hagan, Ana Bernardo-Gancedo, et al.
Nature Communications|July 20, 2017
Silk micrococoons for protein stabilisation and molecular encapsulationUlyana Shimanovich, Francesco S Ruggeri, Erwin De Genst, et al.
The Journal of Physical Chemistry. B|August 8, 2013
A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formationErwin De Genst, Pak-Ho Chan, Els Pardon, et al.
Journal of Molecular Biology|April 6, 2013
Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stagesTim Guilliams, Farah El-Turk, Alexander K Buell, et al.
Molecular Microbiology|January 22, 2005
Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesinJulie Bouckaert, Jenny Berglund, Mark Schembri, et al.
Biochemistry|September 26, 2008
Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrilsPak-Ho Chan, Els Pardon, Linda Menzer, et al.
BMC Biology|July 5, 2017
Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric speciesMarija Iljina, Liu Hong, Mathew H Horrocks, et al.
Nature Communications|May 31, 2022
Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failureErwin De Genst, Kylie S Foo, Yao Xiao, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Discovery of Small-Molecule Ligands for the E3 Ligase STUB1/CHIP from a DNA-Encoded Library ScreenSimon C C Lucas, Alexander G Milbradt, Jason Breed, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Protein Engineering, Design & Selection : PEDS|April 13, 2010
A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosisChristine L Hagan, Russell J K Johnson, Anne Dhulesia, et al.
Biophysical Journal|December 8, 2016
The Significance of the Location of Mutations for the Native-State Dynamics of Human LysozymeMinkoo Ahn, Christine L Hagan, Ana Bernardo-Gancedo, et al.
Nature Communications|July 20, 2017
Silk micrococoons for protein stabilisation and molecular encapsulationUlyana Shimanovich, Francesco S Ruggeri, Erwin De Genst, et al.
The Journal of Physical Chemistry. B|August 8, 2013
A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formationErwin De Genst, Pak-Ho Chan, Els Pardon, et al.
Journal of Molecular Biology|April 6, 2013
Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stagesTim Guilliams, Farah El-Turk, Alexander K Buell, et al.
Molecular Microbiology|January 22, 2005
Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesinJulie Bouckaert, Jenny Berglund, Mark Schembri, et al.
Biochemistry|September 26, 2008
Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrilsPak-Ho Chan, Els Pardon, Linda Menzer, et al.
BMC Biology|July 5, 2017
Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric speciesMarija Iljina, Liu Hong, Mathew H Horrocks, et al.
Nature Communications|May 31, 2022
Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failureErwin De Genst, Kylie S Foo, Yao Xiao, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Discovery of Small-Molecule Ligands for the E3 Ligase STUB1/CHIP from a DNA-Encoded Library ScreenSimon C C Lucas, Alexander G Milbradt, Jason Breed, et al.
Pageof 4